Chromosome 17p Deletion

Categories: Rare diseases

Aliases & Classifications for Chromosome 17p Deletion

MalaCards integrated aliases for Chromosome 17p Deletion:

Name: Chromosome 17p Deletion 54
Chromosome 17p Deletion Syndrome 74
Loss of Chromosome 17p 74
Partial Monosomy 17p 54
17p Deletion 54
17p Monosomy 54
Deletion 17p 54
Monosomy 17p 54


External Ids:

Summaries for Chromosome 17p Deletion

MalaCards based summary : Chromosome 17p Deletion, also known as chromosome 17p deletion syndrome, is related to smith-magenis syndrome and lissencephaly. An important gene associated with Chromosome 17p Deletion is MIR21 (MicroRNA 21). The drugs ofatumumab and Idelalisib have been mentioned in the context of this disorder. Affiliated tissues include b cells, myeloid and t cells.

Related Diseases for Chromosome 17p Deletion

Graphical network of the top 20 diseases related to Chromosome 17p Deletion:

Diseases related to Chromosome 17p Deletion

Symptoms & Phenotypes for Chromosome 17p Deletion

Drugs & Therapeutics for Chromosome 17p Deletion

Drugs for Chromosome 17p Deletion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
ofatumumab Approved Phase 3,Phase 2 679818-59-8 6918251
Idelalisib Approved Phase 3,Phase 2 870281-82-6
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
Venetoclax Approved, Investigational Phase 3,Phase 2 1257044-40-8 49846579
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
8 Pevonedistat Investigational Phase 3 905579-51-3
9 Immunologic Factors Phase 3,Phase 2
10 Antineoplastic Agents, Immunological Phase 3,Phase 2
11 Antimetabolites, Antineoplastic Phase 3,Phase 2
12 Antimetabolites Phase 3,Phase 2
13 Antibodies, Monoclonal Phase 3,Phase 2
14 Antibodies Phase 3,Phase 2
15 Immunoglobulins Phase 3,Phase 2
16 Alkylating Agents Phase 3,Phase 2
17 Bendamustine Hydrochloride Phase 3,Phase 2
18 Antineoplastic Agents, Alkylating Phase 3,Phase 2
19 Angiogenesis Inhibitors Phase 3,Phase 2
20 Angiogenesis Modulating Agents Phase 3,Phase 2
21 Antirheumatic Agents Phase 3,Phase 2
22 Receptors, Antigen, B-Cell Phase 3
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
alemtuzumab Approved, Investigational Phase 2 216503-57-0
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
Pomalidomide Approved Phase 2 19171-19-8
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
30 Daratumumab Approved Phase 2 945721-28-8
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
Pembrolizumab Approved Phase 2 1374853-91-4
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
Ixazomib Approved, Investigational Phase 2 1072833-77-2
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
41 Gastrointestinal Agents Phase 2
42 HIV Protease Inhibitors Phase 2
protease inhibitors Phase 2
44 Autonomic Agents Phase 2
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
46 Hormones Phase 2
47 Antiemetics Phase 2
48 Hormone Antagonists Phase 2
49 Antineoplastic Agents, Hormonal Phase 2
50 Anti-Infective Agents Phase 2

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
2 Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01659021 Phase 3 Idelalisib;Ofatumumab
3 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Recruiting NCT03406156 Phase 3 Obinutuzumab;Bendamustine;Venetoclax
4 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
5 A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor. Active, not recruiting NCT02756611 Phase 3 Venetoclax
6 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). Active, not recruiting NCT02980731 Phase 3 Venetoclax
7 A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy Active, not recruiting NCT01556776 Phase 3 lenalidomide;Placebo
8 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Active, not recruiting NCT02005471 Phase 3 Bendamustine;Venetoclax;Rituximab
9 OraTest in Combination With Visual Examination and Visual Examination Alone Terminated NCT00537199 Phase 3 OraTest
10 Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine Unknown status NCT01392079 Phase 2 Alemtuzumab
11 A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion Completed NCT01744691 Phase 2 Ibrutinib
12 Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) Completed NCT01745640 Phase 2 POMALIDOMIDE;Dexamethasone
13 Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia Completed NCT02015208 Phase 1, Phase 2 Ruxolitinib
14 Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies Completed NCT01966510 Phase 2
15 Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) Completed NCT01520922 Phase 2 Bendamustine
16 HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab Completed NCT00349349 Phase 2 ofatumumab
17 A Study of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion Recruiting NCT02966756 Phase 2 Venetoclax
18 Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction Recruiting NCT03734198 Phase 2 Ibrutinib;Daratumumab
19 BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) Recruiting NCT02834364 Phase 2 Encorafenib;Binimetinib
20 Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma Recruiting NCT03700450 Phase 2 Cyclophosphamide
21 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT03204188 Phase 2 Ibrutinib;Fludarabine;Pembrolizumab
22 A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion Active, not recruiting NCT01889186 Phase 2 ABT-199
23 Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL Active, not recruiting NCT01465334 Phase 2 Ofatumumab;High-Dose Methylprednisolone;Alemtuzumab
24 Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Active, not recruiting NCT02337829 Phase 2 acalabrutinib;acalabrutinib
25 PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT01500733 Phase 2 PCI 32765
26 PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia Active, not recruiting NCT01589302 Phase 2 ibrutinib
27 Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma Active, not recruiting NCT02897830 Phase 2 Ixazomib;Lenalidomide;Dexamethasone
28 Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion Terminated NCT02044822 Phase 2 Idelalisib;Rituximab
29 Treatment Strategies for Children With Smith-Magenis Syndrome Completed NCT00506259 Phase 1 dTR Melatonin (NIH CC PDS);Melatonin CR
30 Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL) Unknown status NCT01675102
31 Natural History Study of Smith-Magenis Syndrome Recruiting NCT00013559
32 Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) Terminated NCT02273856

Search NIH Clinical Center for Chromosome 17p Deletion

Genetic Tests for Chromosome 17p Deletion

Anatomical Context for Chromosome 17p Deletion

MalaCards organs/tissues related to Chromosome 17p Deletion:

B Cells, Myeloid, T Cells, Heart

Publications for Chromosome 17p Deletion

Articles related to Chromosome 17p Deletion:

# Title Authors Year
Chromosome 17p deletion in a case of T-cell acute lymphoblastic lymphoma. ( 25195772 )
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. ( 20393129 )
Hedgehog checkpoints in medulloblastoma: the chromosome 17p deletion paradigm. ( 16290230 )
Chromosome 17p deletion in human medulloblastoma: a missing checkpoint in the Hedgehog pathway. ( 15467454 )

Variations for Chromosome 17p Deletion

Expression for Chromosome 17p Deletion

Search GEO for disease gene expression data for Chromosome 17p Deletion.

Pathways for Chromosome 17p Deletion

GO Terms for Chromosome 17p Deletion

Sources for Chromosome 17p Deletion

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
33 HPO
34 ICD10
35 ICD10 via Orphanet
39 LifeMap
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
56 Novoseek
59 OMIM via Orphanet
63 PubMed
71 SNOMED-CT via Orphanet
73 Tocris
75 UMLS via Orphanet
Loading form....